This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Teceleukin
DrugBank Accession Number
DB15389
Background

Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).

Type
Biotech
Groups
Investigational
Synonyms
  • Teceleukin
External IDs
  • RO-236019

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
H5ZRB188EI
CAS number
136279-32-8

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMelanoma (Skin) Stage IV / Recurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma1
2Active Not RecruitingTreatmentMalignant Solid Neoplasms / Metastatic Colorectal Adenocarcinoma / Metastatic Ovarian carcinoma / Metastatic Pancreatic (Ductal) Adenocarcinoma / Platinum-Resistant Ovarian Carcinoma / Recurrent High Grade Ovarian Serous Adenocarcinoma / Recurrent Ovarian Carcinosarcoma / Refractory Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
1RecruitingTreatmentClinical Stage IV Cutaneous Melanoma AJCC v8 / Cutaneous Melanoma, Stage III / Cutaneous Melanoma, Stage IV / IL13RA2 Positive / Metastatic Melanoma1
1RecruitingTreatmentPediatric Solid Tumors With Lung Metastases / Refractory/Relapse Neuroblastoma1
1, 2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 15:24 / Updated at February 21, 2021 18:55